Papers
1
Total Citations
15
H-Index
1
About
Dr. D. Cantu is a leading gynecologic oncologist whose research has significantly advanced the surgical management of early-stage cervical cancer. Best known for the landmark "23 Concerv" prospective trial (2019), Dr. Cantu challenged conventional radical surgery by demonstrating the safety and efficacy of conservative, fertility-sparing approaches for low-risk patients. This work, which has garnered 15 citations, directly impacts clinical guidelines and offers young women a less morbid path to cure without compromising oncologic outcomes. Beyond this pivotal study, Dr. Cantu’s broader contributions focus on optimizing surgical techniques, reducing treatment-related toxicity, and personalizing care for cervical cancer patients. Their research bridges the gap between aggressive oncologic necessity and quality-of-life preservation, earning recognition as a thought leader in minimally invasive and conservative gynecologic surgery. For students and clinicians, Dr. Cantu’s work exemplifies how rigorous trial design can reshape standard practice, making a tangible difference in patients’ lives while advancing the field toward more nuanced, patient-centered care.
Research Focus
Key Achievements
Top Papers
- 1